Free public records show Taro in 3 of the markets we cover. It is not a key player in our research.
From public registers, not from Acuitas research, with a citation under every number. Each card opens the full list at its source.
80 approvals with a product on the US market
Source: Drugs@FDA, Approvals (NDA, ANDA, BLA) held, with a product sold now; newest shown. Retrieved 13 Nov 2026.
3 recalls since 2015 (3 for medicines)
Source: openFDA, FDA enforcement reports (recalls) naming the firm, since 2015. Retrieved 13 Nov 2026.
Annual reports and other filings with the US Securities and Exchange Commission.
Source: SEC EDGAR, Company filings, CIK 906338.
Markets we cover where free public records show Taro: trials they lead, US approvals or WHO prequalification. Each opens the market's report, with the record counts and their sources.
The topics of the markets Taro is in.
Stories on the topics Taro works in.
Collagen powders promise younger skin and easier joints. A 2025 review of 23 trials found the benefits…
Read
About 321,000 people were diagnosed with brain and nervous system tumours in 2022, and about 248,000 died…
Read
Skin cancers caused over 1.5 million new cases in 2022. Imaging and AI tools are changing how skin conditions…
Read